- GlycoNex partners with Sterling Pharma Solutions for the clinical trial production of GNX102-ADC, a glycan-targeted cancer immunotherapy.
- Sterling Pharma’s ADC manufacturing expertise will support GlycoNex in its Phase 1 program for GNX102-ADC.
GlycoNex, a biotechnology company developing glycan-targeted cancer immunotherapies, has signed a manufacturing agreement with UK-based contract development and manufacturing organisation (CDMO) Sterling Pharma Solutions. The collaboration will enable clinical trial production of GlycoNex’s drug candidate, GNX102-ADC, in preparation for an upcoming Phase 1 clinical program.
GNX102-ADC is an Antibody-Drug Conjugate (ADC) that combines GlycoNex’s monoclonal antibody GNX102 with cytotoxic drugs aimed at targeting cancer cells precisely. GNX102 targets unique tumor-associated glycans to inhibit tumour growth, and the compound has demonstrated strong safety and tolerability in earlier Phase 1 studies. In addition to safety, GNX102-ADC has shown tumour-suppressing potential in animal studies across a range of cancers, including gastric, colorectal, pancreatic, and lung cancers.
Dr. Mei-Chun Yang, CEO of GlycoNex, expressed optimism for the collaboration: “Our GNX102 monoclonal antibody demonstrated superior safety in Phase 1 clinical trials making it an ideal candidate to develop as an ADC. We are excited to benefit from Sterling’s ADC manufacturing expertise in the production of GNX102-ADC.”
Sterling Pharma Solutions, which has an ADC-specialised manufacturing facility in Deeside, UK, will use its clinical-scale GMP capabilities to support GlycoNex’s Phase 1 development efforts. Commenting on the partnership, Chad Telgenhof, Sterling’s Chief Commercial Officer, stated, “This agreement will leverage the expertise we have in clinical-scale GMP manufacturing… and we look forward to building a partnership with GlycoNex to support its ongoing drug development.”
With patents secured for GNX102-ADC across the U.S., Japan, South Korea, Taiwan, and Russia, GlycoNex will retain full development rights as it advances this potential treatment for solid tumour types.
Overview of outsourcing trends 
